Less Risk, More Reward?
With stocks (as with many things), the greater the risk, the greater the reward (and, by virtue, the smaller the risk, the smaller the reward)…right?… Read More »Less Risk, More Reward?
With stocks (as with many things), the greater the risk, the greater the reward (and, by virtue, the smaller the risk, the smaller the reward)…right?… Read More »Less Risk, More Reward?
While 2019 has not been a strong year for healthcare stocks, companies experiencing rapid sales growth – such as some select medical device companies –… Read More »Medtech Moneymakers
While most of the attention is focused on a stock market near all-time highs, there’s money to be made in commodities. Here are three different… Read More »Up, Down & Sideways: Profit From Commodity Trends In All Directions
It has been a disappointing year for marijuana stocks. Fortunately, there’s a simple trick that long-term investors can employ to put themselves in a much… Read More »Recast Your Beaten-Down Marijuana Stocks With This Strategy (While There’s Still Time)
With marijuana investing now moving into the mainstream, the next major investment trend to come out of the drug reform movement could be psychedelic –… Read More »The “Shroom Boom”: A Truly Psychedelic Opportunity
One of the only marijuana stocks that actually makes any money is among a handful of “white-hot” stocks currently trading under $10 that offer more… Read More »Sizable Upside At A Small Price
It may seem counterintuitive so late in the economic cycle, but several analysts are bullish on homebuilder stocks right now – and among the potential… Read More »A “Golden” Opportunity In Homebuilder Stocks
Analysts at one research firm have been able to beat the market decisively in recent years by combining fundamental analysis with quantitative analysis – and… Read More »Beat The Market With “Quant + Fundamental”
The sharp rise in Elizabeth Warren’s poll numbers in the Democratic presidential primary has coincided with a sharp decline in the shares of many biotech… Read More »Biotech Stocks Now Available At A “Warren Discount”
Shares of Facebook are up 35% year to date – and with its low valuation and strong fundamentals, several analysts see the stock as presenting… Read More »The Case For Buying Facebook Ahead Of Earnings